RxDoctor Payments Data

Mohamed Khan, MD

Cardiovascular Disease · Brighton, MANPI 1588740054

Payments from drug & device makers

$29,262in general payments, 2019–2025

Across 55 payments — averaging $532.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$27K
  • Cathworks, Inc.$1K
  • Bayer$237
  • Medtronic$195
  • Boston Scientific$168
  • Abbott$125
  • plus $190 from 4 others
$550in research payments, 2019–2025

Across 1 payment — averaging $550.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Inspiremd Ltd$550

What the payments were for

  • Speaking & faculty fees$25,85091%
  • Travel & lodging$6672%
  • Food & beverage$1,7246%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca39$27,347
Cathworks, Inc.1$1,000
Bayer3$237
Medtronic(2 entities)3$195
Boston Scientific2$168
Abbott1$125
Pfizer2$63
Abiomed1$59
Merck2$45
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)1$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,262 in reported general payments places this provider in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$109,163
Medicare patients
279
Services billed
1,004

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban66$89,792
FarxigaDapagliflozin Propanediol62$55,268
BrilintaTicagrelor17$19,304
JardianceEmpagliflozin15$18,511
Metoprolol Succinate210$3,942
Spironolactone156$1,924
Atorvastatin Calcium147$1,835
Ezetimibe57$1,604
Lisinopril156$1,557
Ranolazine ErRanolazine16$1,438
Rosuvastatin Calcium51$1,413
Losartan Potassium88$1,046
Valsartan23$803
Isosorbide Mononitrate ErIsosorbide Mononitrate32$715
Carvedilol42$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$89,79266 claims
AstraZenecaFarxiga, Brilinta$27,347$74,57279 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Brighton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →